Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
暂无分享,去创建一个
Jean Mosser | Franck Morin | Gérard Zalcman | Frédérique Penault-Llorca | J. Mosser | B. Milleron | S. Lantuejoul | F. Penault-Llorca | J. Soria | J. Mazières | J. Pujol | H. Blons | G. Zalcman | J. Sabourin | J. Merlio | F. Escande | M. Denis | F. Barlesi | L. Ouafik | B. Besse | I. Rouquette | C. Audigier-Valette | P. Bringuier | H. Léna | A. Lemoine | Jean-Charles Soria | Fabrice Barlesi | Jacques Cadranel | Benjamin Besse | L'Houcine Ouafik | R. Veillon | V. Westeel | M. Beau-Faller | F. Morin | D. Debieuvre | I. Monnet | R. Lamy | Q. Tran | P. Missy | A. Langlais | J. Cadranel | Sylvie Lantuejoul | Marc G Denis | Hélène Blons | Julien Mazieres | Isabelle Monnet | Clarisse Audigier-Valette | Bernard Milleron | Hervé Lena | Michèle Beau-Faller | Virginie Westeel | Pascale Missy | Jean-Christophe Sabourin | Antoinette Lemoine | Pierre-Paul Bringuier | Jean-Philippe Merlio | Didier Debieuvre | Isabelle Rouquette | Fabienne Escande | Rémi Veillon | Régine Lamy | Jean-Louis Pujol | Quân Tran | Alexandra Langlais
[1] W. Travis,et al. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Soria,et al. Tumour molecular profiling for deciding therapy—the French initiative , 2012, Nature Reviews Clinical Oncology.
[3] S. Peters,et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[5] C. Rudin,et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. , 2013 .
[6] T. Nakajima,et al. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single‐institute study , 2014, Cancer.
[7] Thomas J. Smith,et al. 美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[8] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[9] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[10] F. André,et al. Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups , 2012, Clinical Cancer Research.
[11] E. Brambilla,et al. Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] M. Tsao,et al. KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[14] G. Chatellier,et al. Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience , 2013, PloS one.
[15] D De Ruysscher,et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] A. Iafrate,et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). , 2014 .
[17] J. Crowley,et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[19] J. Pignon,et al. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. , 2014, The Journal of molecular diagnostics : JMD.
[20] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[21] A. Iafrate,et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. , 2011, The Journal of molecular diagnostics : JMD.
[22] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[23] J. Soria,et al. Europe does it better: molecular testing across a national health care system-the French example. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[24] Thomas J. Smith,et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Touboul,et al. Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000) , 2003, British Journal of Cancer.
[26] S. Digumarthy,et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.